Chronic Lymphocytic Leukemia

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.

Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

The in vivo CAR T-cell therapy UB-VV111 has received fast track designation from the FDA for the management of relapsed/refractory LBCL and CLL.

Workshop faculty shared insights on first-line, R/R, and post-BTKi CLL care, plus sequencing, shared decision-making, and emerging therapies.

Paolo Ghia, MD, provided insights into the significance of updated data from the final analysis of the phase 2 CAPTIVATE study in CLL/SLL.

Cyrus M. Khan, MD, discusses the key BTK inhibitor updates for the treatment of patients with relapsed/refractory CLL from the 2025 ASCO Annual Meeting.

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Paolo Ghia, MD, PhD, discusses the safety considerations of fixed-duration ibrutinib plus venetoclax after retreatment in patients with CLL.

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Kathleen A. Dorritie, MD, discusses data that inform the use of pirtobrutinib and liso-cel for the treatment of patients with chronic lymphocytic leukemia.

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

Topline results from the BRUIN CLL-313 study show a significant improvement in PFS with pirtobrutinib vs chemoimmunotherapy in treatment-naive CLL/SLL.

Mazyar Shadman, MD, MPH, details the rationale for investigating the combination of zanubrutinib and venetoclax in treatment-naive CLL/SLL.

Zanubrutinib bested acalabrutinib plus venetoclax in terms of PFS in patients with treatment-naive, low-risk CLL.

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

Cyrus M. Khan, MD, detailed the development of second-generation BTK inhibitors and how they compare with first-generation BTK inhibitors in CLL.

In an OncLive® Peer Exchange, 4 panelists discuss navigating fixed-duration vs continuous therapy in CLL.

Kathleen A. Dorritie, MD, details the difference in care between the management of untreated CLL and relapsed/refractory CLL.

Venetoclax plus obinutuzumab generated safe and efficacious real-world outcomes in first-line CLL with comorbidities.

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL